SAN DIEGO, June 1, 2021 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced abstracts and
presentations by its collaborators for the 2021 American Society of
Clinical Oncology (ASCO) Annual Meeting, which will be held
June 4-8, 2021.
Janssen Research & Development, LLC (Janssen)-sponsored
study with therapeutics utilizing ENHANZE®
technology:
Subcutaneous daratumumab in combination with bortezomib,
cyclophosphamide, and dexamethasone (VCd) in patients with newly
diagnosed light chain (AL) amyloidosis
- Oral abstract session: Updated results from the Phase 3
ANDROMEDA study of DARZALEX FASPRO® in combination with
bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the
treatment of newly diagnosed AL amyloidosis (Abstract #8003).
Bristol Myers Squibb-sponsored
study with therapeutics utilizing ENHANZE®
technology:
CheckMate 8KX: Phase 1/2 multi-tumor preliminary analyses of a
subcutaneous formulation of nivolumab (± rHuPH20)
- Poster session: The first data on the pharmacokinetics (PK),
safety, tolerability, and pharmacodynamics (PD) of subcutaneous
nivolumab + rHuPH20 (Abstract #2575).
Roche-sponsored study with therapeutics utilizing
ENHANZE® technology:
Potential non-drug cost differences associated with the use of
the fixed-dose combination of pertuzumab and trastuzumab for
subcutaneous injection (PH FDC SC) in the treatment of
HER2-positive early breast cancer patients in Western Europe and the United States
- Poster session: The aim of this study is to estimate the
incremental difference in non-drug costs between PH FDC SC and PT
IV for a typical patient receiving treatment for HER2-positive
early breast cancer in Western
Europe and the United
States (Abstract #544).
About Halozyme
Halozyme is a biopharmaceutical company
bringing disruptive solutions to significantly improve patient
experiences and outcomes for emerging and established therapies.
Halozyme advises and supports its biopharmaceutical partners in key
aspects of new drug development with the goal of improving
patients' lives while helping its partners achieve global
commercial success. As the innovators of the ENHANZE®
technology, which can reduce hours-long treatments to a matter of
minutes, Halozyme's commercially-validated solution has positively
impacted more than 500,000 patient lives via five commercialized
products across more than 100 global markets. Halozyme and its
world-class partners are currently advancing multiple therapeutic
programs intended to deliver innovative therapies, with the
potential to improve the lives of patients around the globe.
Halozyme's proprietary enzyme rHuPH20 forms the basis of the
ENHANZE® technology and is used to facilitate the
delivery of injected drugs and fluids, potentially reducing the
treatment burden of other drugs to patients. Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon
Therapeutics. Halozyme derives revenues from these collaborations
in the form of milestones and royalties as the Company's partners
make progress developing and commercializing their products being
developed with ENHANZE®. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Safe Harbor Statement
In addition to historical
information, the statements set forth above include forward-looking
statements including, without limitation, statements concerning the
possible activity, benefits and attributes of ENHANZE®,
the possible method of action of ENHANZE®, its potential
application to aid in the dispersion and absorption of other
injected therapeutic drugs, and statements concerning certain other
potential benefits of ENHANZE® including facilitating
more rapid delivery of injectable medications through subcutaneous
delivery and potentially lowering the treatment burden for
patients. These forward-looking statements also include statements
regarding the product development efforts of Halozyme's
ENHANZE® partner. These forward-looking statements
involve risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements. The
forward-looking statements are typically, but not always,
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including uncertainties concerning whether collaborative products
are ultimately developed, approved or commercialized, unexpected
expenditures and costs, unexpected results or delays in development
and regulatory review including any potential delays caused by the
current COVID-19 global pandemic, unexpected regulatory approval
requirements, unexpected adverse events or patient outcomes from
being treated with the ENHANZE® co-formulated treatment
referred to in this press release, and competitive conditions.
These and other factors that may result in differences are
discussed in greater detail in Halozyme's most recent Annual and
Quarterly Reports filed with the Securities and Exchange
Commission. Except as required by law, Halozyme undertakes no duty
to update forward-looking statements to reflect events after the
date of this release.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-highlights-data-presentations-by-collaborators-for-therapies-utilizing-enhanze-at-2021-american-society-of-clinical-oncology-asco-annual-meeting-301303245.html
SOURCE Halozyme Therapeutics, Inc.